ARANZ Medical’s Pedigree in Clinical Trials Makes Silhouette(R) the Obvious Choice for New Research

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

April 24, 2018

ARANZ Medical reports their Silhouette skin imaging and measuring solutions have powered more than 100 clinical trials since 2007, and are proving to be a reliable choice for companies undertaking multi-center clinical trials.

The company reports ProQR Therapeutics is the latest clinical research customer to choose SilhouetteStar and the new SilhouetteLite+ solutions to provide the skin imaging and documentation for their study into the drug QR-313 for Dystrophic Epidermolysis Bullosa (DEB).

Epidermolysis Bullosa (EB) is a group of rare, mainly inherited genetic skin diseases (of which Dystrophic EB is one of the most severe forms) that causes skin to be fragile and blister.  The term “Butterfly Children” is often used to describe younger EB patients because the skin is said to be as fragile as a butterfly’s wings.  While there is currently no cure for EB, companies like ProQR are actively looking for new therapies to help improve the quality of life for these patients.  Silhouette has already been used in 5 clinical trials for EB therapies including the largest EB study in the world.

With study sites in both the US and Europe, Silhouette will make it easier for ProQR to collect and analyse the data.  “ProQR is excited to collaborate with ARANZ Medical and utilize Silhouette and particularly SilhouetteLite+ for the first time to remotely monitor EB wounds in our upcoming WINGS study of QR-313 in Dystrophic Epidermolysis Bullosa (DEB).  This patient centric technology will enable us to reduce the significant travel burden for patients to clinical trial sites,” says the Clinical Outcomes Measures Specialist at ProQR.

Silhouette has been employed in pre-clinical to post-market studies with the largest study to date having more than 200 imaging devices spread over sites in 13 countries.  Study indications include Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcers, Epidermolysis Bullosa, as well as for various dermatology conditions.  More than 120,000 subject assessments have been captured and processed with Silhouette in the course of these clinical trials.

“Our Silhouette product suite is a flexible and robust solution for imaging and making accurate measurements of features on the surface of the body and storing that information securely,” said ARANZ Medical CEO, Bruce Davey.  He concluded, “And with our wide ranging experience in supporting clinical trials of all phases and many indications, our team can provide comprehensive support and consulting to improve trial success.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.